carbostyril has been researched along with Huntington Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 10 (71.43) | 24.3611 |
| 2020's | 2 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Funayama, M; Mimura, M; Mimura, Y; Oi, H; Takata, T; Takeuchi, H | 1 |
| Caron, MC; Chiang, K; Davidson, S; Edward, LM; Eichler, EE; Gall-Duncan, T; Gallon, R; Hayakawa, H; Huddleston, J; Joshi, N; Lanni, S; Layeghifard, M; Lee, MYWT; Li, J; Luo, J; Masson, JY; Mochizuki, H; Munson, KM; Murata, A; Nakamori, M; Nakatani, K; Otabe, T; Panigrahi, GB; Pearson, CE; Prasolava, T; Sakata, A; Santibanez-Koref, M; Shlien, A; Takahashi, MP; Tanaka, H; Wang, X; Wold, MS | 1 |
| Blusch, A; Brunner, J; Ellrichmann, G; Fatoba, O; Gold, R; Hayardeny, L; Hayden, M; Reick, C; Saft, C; Sehr, D; Winklhofer, KF | 1 |
| Elgart, A; Eyal, E; Mimrod, D; Morganroth, J; Rabinovich, L; Samara, E; Spiegelstein, O; Sprenger, C | 1 |
| Belinson, H; Garcia-Miralles, M; Hayden, MR; Pouladi, MA; Radulescu, CI; Sidik, H; Tan, JY; Tan, LJ; Yusof, NABM; Zach, N | 1 |
| Edlinger, M; Fleischhacker, W; Hofer, A; Seppi, K | 1 |
| Alnıak, İ; Ulusoy, S; Yavuz, KF | 1 |
| Dobson, L; Farmer, R; Hayardeny, L; Hayden, MR; Loupe, P; Tabrizi, SJ; Träger, U | 1 |
| Björkqvist, M | 1 |
| Caron, NS; Chuang, KH; Franciosi, S; Garcia-Miralles, M; Hayardeny, L; Hayden, MR; Hong, X; Huang, Y; Lin, RY; Papapetropoulos, S; Pouladi, MA; Tan, LJ; To, XV | 1 |
| Chou, YH; Lin, WC | 1 |
| Bernardi, G; Brusa, L; Iani, C; Mercuri, NB; Moschella, V; Orlacchio, A | 1 |
| Abler, B; Gahr, M; Orth, M | 1 |
| Konstantakopoulos, G; Kouzoupis, AV; Mourikis, I; Oulis, P; Papageorgiou, SG | 1 |
2 trial(s) available for carbostyril and Huntington Disease
| Article | Year |
|---|---|
A Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.
Topics: Adolescent; Adult; Double-Blind Method; Electrocardiography; Female; Heart; Heart Rate; Humans; Huntington Disease; Immunologic Factors; Long QT Syndrome; Male; Middle Aged; Multiple Sclerosis; Quinolones; Young Adult | 2019 |
Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine.
Topics: Adult; Aged; Aripiprazole; Cross-Over Studies; Dopamine Agents; Dyskinesia, Drug-Induced; Female; Humans; Huntingtin Protein; Huntington Disease; Hyperkinesis; Male; Middle Aged; Nerve Tissue Proteins; Nuclear Proteins; Piperazines; Quinolones; Receptors, Dopamine D2; Tetrabenazine; Trinucleotide Repeats | 2009 |
12 other study(ies) available for carbostyril and Huntington Disease
| Article | Year |
|---|---|
Effectiveness of brexpiprazole in the treatment in a patient with Huntington's disease.
Topics: Adult; Dopamine Agonists; Humans; Huntington Disease; Male; Quinolones; Thiophenes | 2020 |
A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo.
Topics: Animals; Corpus Striatum; Disease Models, Animal; DNA; DNA Mismatch Repair; DNA Replication; Humans; Huntingtin Protein; Huntington Disease; Male; Mice; Mice, Transgenic; Microsatellite Instability; Mutation; Naphthyridines; Quinolones; Ribonucleases; TATA-Box Binding Protein; Transcription, Genetic; Trinucleotide Repeat Expansion | 2020 |
Laquinimod treatment in the R6/2 mouse model.
Topics: Animals; Biomarkers; Body Weight; Brain-Derived Neurotrophic Factor; Cell Survival; Disease Models, Animal; Energy Metabolism; Fluorescent Antibody Technique; Gene Expression; Huntington Disease; Mice; Mice, Transgenic; Motor Activity; Neurons; PC12 Cells; Quinolones; Rats; Survival Rate | 2017 |
Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease.
Topics: Animals; Astrocytes; Behavior, Animal; Cell Count; Corpus Callosum; Corpus Striatum; Cytochrome P-450 CYP1A1; Depression; Disease Models, Animal; Female; Gene Expression Regulation; Humans; Huntington Disease; Inflammation; Learning; Male; Mice, Transgenic; Microglia; Motor Activity; Myelin Sheath; Oligodendroglia; Phenotype; Quinolones; Receptors, Aryl Hydrocarbon; Transcription, Genetic | 2019 |
Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease.
Topics: Adult; Aggression; Antipsychotic Agents; Aripiprazole; Clozapine; Drug Therapy, Combination; Humans; Huntington Disease; Male; Morpholines; Piperazines; Psychotic Disorders; Quinolones; Reboxetine; Treatment Outcome | 2013 |
Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Athetosis; Chorea; Humans; Huntington Disease; Piperazines; Psychotic Disorders; Quinolones | 2013 |
Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells.
Topics: Adult; Aged; Cells, Cultured; Cytokines; Dose-Response Relationship, Drug; Female; Humans; Huntington Disease; Male; Middle Aged; Myeloid Cells; Quinolones | 2016 |
Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?
Topics: Animals; Cytokines; Humans; Huntington Disease; Immunologic Factors; Immunomodulation; Microglia; Quinolones; Treatment Outcome | 2016 |
Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease.
Topics: Animals; Behavior, Animal; Corpus Striatum; Diffusion Tensor Imaging; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Huntington Disease; Interleukin-6; Male; Mice; Quinolones; White Matter | 2016 |
Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Huntington Disease; Male; Middle Aged; Piperazines; Psychotic Disorders; Quinolones | 2008 |
Neuroleptic malignant syndrome with aripiprazole in Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Humans; Huntington Disease; Male; Middle Aged; Neuroleptic Malignant Syndrome; Piperazines; Quinolones | 2010 |
Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Humans; Huntington Disease; Male; Middle Aged; Olanzapine; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Treatment Outcome | 2010 |